血液骨转换标志物PINP与β-CTX检测的分析考量及标准化或一致化计划
国际骨质疏松基金会(IOF)与国际临床化学和实验室医学联盟(IFCC)将血PINP和β-CTX指定为骨质疏松参考骨转换标志物。IFCC骨代谢委员会(C-BM)检查了当前商业检测并开展多中心研究,评估血清和血浆中PINP与β-CTX检测间的一致性,以推动PINP检测一致化和β-CTX检测标准化。
要点
- PINP和β-CTX被IOF与IFCC指定为骨质疏松参考骨转换标志物。
- IFCC C-BM开展多中心研究评估血清和血浆中PINP与β-CTX商业检测间一致性。
- 计划通过通用校准品和参考测量程序实现PINP一致化和β-CTX标准化。
核心结论
- 多中心研究结果将指导PINP检测一致化和β-CTX检测标准化工作。
研究设计与样本
- IFCC骨代谢委员会检查当前商业检测并开展多中心研究,评估血清和血浆中PINP与β-CTX检测间的一致性。
临床怎么用
- 与试剂制造商合作开发通用校准品和参考测量程序,以实现PINP一致化和β-CTX标准化。
- 成功实现上述目标有助于制定普遍可接受的骨质疏松管理实践指南,包括PINP和β-CTX的通用参考区间和治疗目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Procollagen type I N-propeptide (PINP) and the C-terminal telopeptide of type I collagen (β-CTX) in blood have been designated as reference bone turnover markers in osteoporosis by the International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). The IFCC Committee on Bone Metabolism (C-BM) has examined current commercial assays and performed a multicentre study to examine the agreement between assays for PINP and β-CTX in serum and plasma. The results of these studies will inform our work towards the harmonization of PINP assays and the standardization of β-CTX assays in blood, with the development of common calibrators and reference measurement procedures in collaboration with the reagent manufacturing industry. Successful achievement of these goals will help develop universally acceptable practice guidelines for the management of osteoporosis with the inclusion of common reference intervals and treatment targets for PINP and β-CTX.
引用
- Bhattoa HP, Cavalier E, Eastell R, et al. Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood. Clin Chim Acta. 2020. PMID: 33382995. doi:10.1016/j.cca.2020.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。